pomalidomide has been researched along with navitoclax in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (navitoclax) | Trials (navitoclax) | Recent Studies (post-2010) (navitoclax) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 429 | 15 | 401 |
| Protein | Taxonomy | pomalidomide (IC50) | navitoclax (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.0043 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0091 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0168 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 1.0925 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, S; Ezell, EL; King, HM; Kizhake, S; Kubica, SP; Law, HC; Mallareddy, JR; Naldrett, MJ; Natarajan, A; Rana, S; Woods, NT; Zahid, M | 1 |
1 other study(ies) available for pomalidomide and navitoclax
| Article | Year |
|---|---|
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cyclin-Dependent Kinase 9; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2021 |